Integrating Clinical Pharmacy Services Into Comprehensive Multiple Sclerosis Care Teams: A Narrative Review of 4 Models.

Q1 Nursing
International journal of MS care Pub Date : 2025-04-21 eCollection Date: 2025-04-01 DOI:10.7224/1537-2073.2024-019
Nina Bozinov, Autumn Ramsrud, Jenelle H Montgomery, Steven Merrill, Sarah N Rajkovic, Kavita V Nair
{"title":"Integrating Clinical Pharmacy Services Into Comprehensive Multiple Sclerosis Care Teams: A Narrative Review of 4 Models.","authors":"Nina Bozinov, Autumn Ramsrud, Jenelle H Montgomery, Steven Merrill, Sarah N Rajkovic, Kavita V Nair","doi":"10.7224/1537-2073.2024-019","DOIUrl":null,"url":null,"abstract":"<p><p><b>BACKGROUND:</b> Over the past 30 years, the treatment landscape for multiple sclerosis (MS) has become increasingly complex. All MS disease-modifying therapies (DMTs) and several symptomatic medications are designated specialty medications, and their financial coverage is subject to complicated insurance processes and a wide array of patient support programs. Many patients receiving MS DMTs need ongoing monitoring or enrollment in a Risk Evaluation and Mitigation Strategy program. Integrated pharmacy services can facilitate financial, technical, and educational aspects of providing specialty medications. Although pharmacy services are often part of the care team for patients with complex chronic medical conditions, MS clinics may not have the benefit of full pharmacy services. We present 4 models of MS health care delivery and discuss how integrating pharmacy services into an MS multidisciplinary team can potentially increase the efficiency and quality of health care delivery. Clinical pharmacists, working with other providers, can optimize and accelerate access to medications requiring prior authorization, improve patient outcomes by promoting medication adherence and persistence, enhance safety by monitoring laboratory findings and potential drug-drug interactions, and minimize clinical workflow burden by improving process efficiency, which may be cost-effective for the MS health care delivery system.</p>","PeriodicalId":14150,"journal":{"name":"International journal of MS care","volume":"27 Q2","pages":"117-124"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12018691/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of MS care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7224/1537-2073.2024-019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Nursing","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND: Over the past 30 years, the treatment landscape for multiple sclerosis (MS) has become increasingly complex. All MS disease-modifying therapies (DMTs) and several symptomatic medications are designated specialty medications, and their financial coverage is subject to complicated insurance processes and a wide array of patient support programs. Many patients receiving MS DMTs need ongoing monitoring or enrollment in a Risk Evaluation and Mitigation Strategy program. Integrated pharmacy services can facilitate financial, technical, and educational aspects of providing specialty medications. Although pharmacy services are often part of the care team for patients with complex chronic medical conditions, MS clinics may not have the benefit of full pharmacy services. We present 4 models of MS health care delivery and discuss how integrating pharmacy services into an MS multidisciplinary team can potentially increase the efficiency and quality of health care delivery. Clinical pharmacists, working with other providers, can optimize and accelerate access to medications requiring prior authorization, improve patient outcomes by promoting medication adherence and persistence, enhance safety by monitoring laboratory findings and potential drug-drug interactions, and minimize clinical workflow burden by improving process efficiency, which may be cost-effective for the MS health care delivery system.

将临床药学服务整合到综合多发性硬化症护理团队:4种模式的叙述性回顾。
背景:在过去的30年里,多发性硬化症(MS)的治疗前景变得越来越复杂。所有MS疾病改善疗法(dmt)和几种症状性药物都被指定为专科药物,其财务覆盖范围受制于复杂的保险流程和广泛的患者支持计划。许多接受MS dmt治疗的患者需要持续监测或纳入风险评估和缓解策略计划。综合药房服务可以促进提供专业药物的财政、技术和教育方面的工作。尽管药房服务通常是复杂慢性疾病患者护理团队的一部分,但多发性硬化症诊所可能没有全面药房服务的好处。我们提出了多发性硬化症医疗保健服务的4种模式,并讨论了如何将药房服务整合到多发性硬化症多学科团队中,以潜在地提高医疗保健服务的效率和质量。临床药师与其他提供者合作,可以优化和加速获得需要事先授权的药物,通过促进药物依从性和持久性来改善患者的结果,通过监测实验室结果和潜在的药物-药物相互作用来提高安全性,并通过提高流程效率来减少临床工作流程负担,这可能对MS医疗保健提供系统具有成本效益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International journal of MS care
International journal of MS care Nursing-Advanced and Specialized Nursing
CiteScore
3.00
自引率
0.00%
发文量
40
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信